Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eleutherakis-Papaiakovou, V.
Right arrow Articles by Dimopoulos, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eleutherakis-Papaiakovou, V.
Right arrow Articles by Dimopoulos, M. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1151-1160, 2004
© 2004 European Society for Medical Oncology

Review

Thalidomide in cancer medicine

Thalidomide, an oral agent with antiangiogenic and immunomodulatory properties, is being investigated extensively in the management of advanced cancer. Multiple studies with large numbers of patients have confirmed that this drug has significant activity in multiple myeloma. Some patients with myelofibrosis or myeodysplatic syndromes may reduce their need for transfusions after thalidomide treatment. The activity of thalidomide in solid tumors is less prominent. Studies in Kaposi's sarcoma, malignant melanoma, renal cell carcinoma and prostate cancer appear more promising especially when thalidomide is combined with biological agents or with chemotherapy. Limited activity was demonstrated in patients with glioma, while thalidomide appears to be inactive in patients with head and neck cancer, breast or ovarian cancer.

V. Eleutherakis-Papaiakovou, A. Bamias and M. A. Dimopoulos*

Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece

* Correspondence to: Dr M. A. Dimopoulos, 227 Kifissias Avenue, Kifissia, Athens 14561, Greece. Tel: +30-210-3381541; Fax: +30-210-8131383; Email: mdimop{at}med.uoa.gr

Key words: angiogenesis, antiangiogenic therapy, cancer, myeloma, thalidomide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Palliat MedHome page
K Lambert and J Ward
The use of thalidomide in the management of bleeding from a gastric cancer
Palliative Medicine, July 1, 2009; 23(5): 473 - 475.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S.-C. Mei and R.-T. Wu
The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Mol. Cancer Ther., August 1, 2008; 7(8): 2405 - 2414.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. X. Zhu
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?
Oncologist, July 1, 2006; 11(7): 790 - 800.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M Stroud
Thalidomide and cancer cachexia: old problem, new hope?
Gut, April 1, 2005; 54(4): 447 - 448.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.